Author:
Konitsiotis Spiridon,Tsironis Christos,Kiortsis Dimitrios N.,Evangelou Angelos
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Andreassen OA, Aamo TO, Joorgensen HA (1996) Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br J Pharmacol 119:751–757
2. Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, Jorgensen HA (2003) Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 122:717–725
3. Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM (1997) A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 17:88–99
4. Blanchet PJ, Metman LV, Mouradian MM, Chase TN (1996) Acute pharmacologic blockade of dyskinesias in Parkinson’s disease. Mov Disord 11:580–581
5. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN (1999) Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-Methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 290:1034–1040